Ascentage Pharma Group Stock Performance
| AAPG Stock | 27.88 1.39 5.25% |
The firm shows a Beta (market volatility) of 0.83, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Ascentage Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ascentage Pharma is expected to be smaller as well. At this point, Ascentage Pharma has a negative expected return of -0.42%. Please make sure to confirm Ascentage Pharma's value at risk, rate of daily change, and the relationship between the total risk alpha and kurtosis , to decide if Ascentage Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Ascentage Pharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Actual Historical Performance (%)
One Day Return 5.25 | Five Day Return (3.23) | Year To Date Return 60.41 | Ten Year Return 60.41 | All Time Return 60.41 |
1 | Why analysts maintain buy rating on Ascentage Pharma Group International stock - Weekly Stock Recap Weekly Return Optimization Alerts - newser.com | 11/18/2025 |
2 | Assessing Ascentage Pharma Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype - simplywall.st | 11/26/2025 |
3 | Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 | 12/01/2025 |
4 | Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph ALL Cleared by US FDA and EMA | 12/05/2025 |
5 | ASH 2025 Ascentage Pharma Presents Encouraging Data from Phase IbII Study of Bcl-2 Inhibitor Lisaftoclax in VenetoclaxExposed Patients with Myeloid Malignances | 12/08/2025 |
6 | ASH 2025 Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph ALL Shows a Best MRD-Negativity CR Rate ... | 12/09/2025 |
7 | Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference | 12/17/2025 |
8 | Ascentage Pharma Group International Stock Price Down 5.5 percent - Should You Sell - MarketBeat | 12/22/2025 |
| Begin Period Cash Flow | 1 B | |
| Total Cashflows From Investing Activities | -362 M |
Ascentage | Build AI portfolio with Ascentage Stock |
Ascentage Pharma Relative Risk vs. Return Landscape
If you would invest 3,783 in Ascentage Pharma Group on September 25, 2025 and sell it today you would lose (995.00) from holding Ascentage Pharma Group or give up 26.3% of portfolio value over 90 days. Ascentage Pharma Group is currently does not generate positive expected returns and assumes 3.4914% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Ascentage, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ascentage Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascentage Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ascentage Pharma Group, and traders can use it to determine the average amount a Ascentage Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.121
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AAPG |
Based on monthly moving average Ascentage Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ascentage Pharma by adding Ascentage Pharma to a well-diversified portfolio.
Ascentage Pharma Fundamentals Growth
Ascentage Stock prices reflect investors' perceptions of the future prospects and financial health of Ascentage Pharma, and Ascentage Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascentage Stock performance.
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (2.97) % | ||||
| Operating Margin | (2.37) % | ||||
| Current Valuation | 2.62 B | ||||
| Shares Outstanding | 92.96 M | ||||
| Price To Book | 26.03 X | ||||
| Price To Sales | 6.34 X | ||||
| Revenue | 980.65 M | ||||
| Gross Profit | 354.93 M | ||||
| EBITDA | (237.63 M) | ||||
| Net Income | (395.25 M) | ||||
| Total Debt | 1.67 B | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (111.36 M) | ||||
| Earnings Per Share | (2.06) X | ||||
| Market Capitalization | 2.48 B | ||||
| Total Asset | 2.62 B | ||||
| Retained Earnings | (5.77 B) | ||||
| Working Capital | 307.55 M | ||||
About Ascentage Pharma Performance
By analyzing Ascentage Pharma's fundamental ratios, stakeholders can gain valuable insights into Ascentage Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ascentage Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ascentage Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 82.79 | 78.65 | |
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.25) | (0.27) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (1.53) | (1.61) |
Things to note about Ascentage Pharma performance evaluation
Checking the ongoing alerts about Ascentage Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ascentage Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ascentage Pharma generated a negative expected return over the last 90 days | |
| Ascentage Pharma has high historical volatility and very poor performance | |
| Ascentage Pharma has a very high chance of going through financial distress in the upcoming years | |
| Ascentage Pharma Group was previously known as AAPGV Old and was traded on NASDAQ Exchange under the symbol AAPGV. | |
| The company reported the previous year's revenue of 980.65 M. Net Loss for the year was (395.25 M) with profit before overhead, payroll, taxes, and interest of 354.93 M. | |
| Ascentage Pharma generates negative cash flow from operations | |
| Ascentage Pharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Ascentage Pharma Group International Stock Price Down 5.5 percent - Should You Sell - MarketBeat |
- Analyzing Ascentage Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascentage Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascentage Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascentage Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascentage Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascentage Pharma's stock. These opinions can provide insight into Ascentage Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ascentage Stock analysis
When running Ascentage Pharma's price analysis, check to measure Ascentage Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascentage Pharma is operating at the current time. Most of Ascentage Pharma's value examination focuses on studying past and present price action to predict the probability of Ascentage Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascentage Pharma's price. Additionally, you may evaluate how the addition of Ascentage Pharma to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |